全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Contribution of 18F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience

DOI: 10.1155/2012/412585

Full-Text   Cite this paper   Add to My Lib

Abstract:

Increased amino acid uptake has been demonstrated in intracerebral tumours and head and neck carcinomas of squamous cell origin. We investigated the potential impact of using 18F-fluoro-ethyl-tyrosine (18F-FET)-PET/CT in addition to conventional imaging for gross tumour volume (GTV) delineation in stereotactic radiotherapy of skull base tumours. The study population consisted of 14 consecutive patients with cranial base tumours (10 with squamous cell histology, 4 others). All patients underwent a FET-PET/CT examination in addition to contrast-enhanced CT and 11 patients underwent MRI. All tumours and histologic types showed increased FET uptake. The GTV was defined by all voxels showing hyperintensity in MRI or CT (GTVMRI/CT) or enhancement in PET (GTVPET), forming a GTVcomposite that was used for the initial treatment fields. An additional volume of infiltrative growth outside the GTVMRI/CT of about 1.0 ± 2 cm3 (5% of the conventional volume) was demonstrated by FET-PET only (GTVPETplus) with significant enlargement (>10% of GTVMRI/CT) in three patients. From existing data, we found correlation between cellular density and the standardized uptake value (SUV) of FET. We were able to substantially reduce the volume of escalated radiation dose (GTVboost) by 11 ± 2 cm3 (24%) of the conventional volume. 1. Introduction It is assumed that the larger part of geometrical uncertainties in fractionated stereotactic radiotherapy (FSRT) is due to delineation errors during the treatment planning procedure [1]. This is especially serious if the errors lead to marginal tumour misses, resulting in a dismal prognosis, or to enlargement of the volume treated, increasing the frequency of severe late effects. Structures of the skull base (SB) with high signal intensity and high contrast-enhancement in magnetic resonance imaging (MRI) make it difficult to differentiate tumour tissue from normal structures [2] and to exactly delineate the target volume. Therefore, although costly, functional imaging is increasingly used for target volume delineation in SB radiotherapy. The diagnostic value of 2-((18)F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for imaging intracranial tumours is hampered by the low imaging contrast between tumourous tissue and that of the normal brain due to the high glucose utilization of both and this may also be true for SB tumours and the neighbouring brain tissue [3]. The newly introduced tracer O-(2-[18F] Fluoro-Ethyl)-L-Tyrosine (18F-FET) allows a more precise estimation of intracerebral tumour borders than MRI [4]. Pauleit et

References

[1]  A. L. Grosu, W. A. Weber, S. T. Astner et al., “11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 2, pp. 339–344, 2006.
[2]  D. D. Durden and D. W. Williams III, “Radiology of skull base neoplasms,” Otolaryngologic Clinics of North America, vol. 34, no. 6, pp. 1043–1064, 2001.
[3]  R. T. Ullrich, L. W. Kracht, and A. H. Jacobs, “Neuroimaging in patients with gliomas,” Seminars in Neurology, vol. 28, no. 4, pp. 484–494, 2008.
[4]  K. J. Langen, K. Hamacher, M. Weckesser et al., “O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications,” Nuclear Medicine and Biology, vol. 33, no. 3, pp. 287–294, 2006.
[5]  D. Pauleit, A. Zimmermann, G. Stoffels et al., “18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer,” Journal of Nuclear Medicine, vol. 47, no. 2, pp. 256–261, 2006.
[6]  A. L. Grosu, S. T. Astner, E. Riedel et al., “An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- andL-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 4, pp. 1049–1058, 2011.
[7]  F. Stockhammer, M. Plotkin, H. Amthauer, F. K. van Landeghem, and C. Woiciechowsky, “Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas,” Journal of Neuro-Oncology, vol. 88, no. 2, pp. 205–210, 2008.
[8]  J. M. Derlon, M. C. Petit-Taboué, F. Chapon et al., “The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine,” Neurosurgery, vol. 40, no. 2, pp. 276–287, 1997.
[9]  Y. Okita, M. Kinoshita, T. Goto et al., “11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison,” NeuroImage, vol. 49, no. 4, pp. 2977–2982, 2010.
[10]  R. L. Wahl, J. M. Herman, and E. Ford, “The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy,” Seminars in Radiation Oncology, vol. 21, no. 2, pp. 88–100, 2011.
[11]  M. Alber, F. Paulsen, S. M. Eschmann, and H. J. Machulla, “On biologically conformal boost dose optimization,” Physics in Medicine and Biology, vol. 48, no. 2, pp. N31–N35, 2003.
[12]  M. D. Piroth, M. Pinkawa, R. Holy, et al., “Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas: results of a prospective phase II study,” Strahlentherapie und Onkologie, vol. 188, no. 4, pp. 334–339, 2012.
[13]  F. Nyuyki, M. Plotkin, R. Graf et al., “Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 310–318, 2010.
[14]  S. T. Astner, M. Dobrei-Ciuchendea, M. Essler et al., “Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 4, pp. 1161–1167, 2008.
[15]  M. L. Calcagni, G. Galli, A. Giordano, et al., “Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy,” Clinical Nuclear Medicine, vol. 36, no. 10, pp. 841–847, 2011.
[16]  G. P?pperl, F. W. Kreth, J. H. Mehrkens et al., “FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 12, pp. 1933–1942, 2007.
[17]  W. A. Weber, H. J. Wester, A. L. Grosu et al., “O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study,” European Journal of Nuclear Medicine, vol. 27, no. 5, pp. 542–549, 2000.
[18]  D. Pauleit, G. Stoffels, W. Schaden et al., “PET with O-(2-18F-fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results,” Journal of Nuclear Medicine, vol. 46, no. 3, pp. 411–416, 2005.
[19]  S. Balogova, S. Périé, K. Kerrou et al., “Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma,” Molecular Imaging and Biology, vol. 10, no. 6, pp. 364–373, 2008.
[20]  S. K. Haerle, D. R. Fischer, D. T. Schmid, N. Ahmad, G. F. Huber, and A. Buck, “18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT,” Molecular Imaging and Biology, vol. 13, no. 5, pp. 1036–1042, 2011.
[21]  S. H. Ng, S. C. Chan, T. C. Yen et al., “Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 12–22, 2009.
[22]  M. Bayne, R. J. Hicks, S. Everitt et al., “Reproducibility of “intelligent” contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 4, pp. 1151–1157, 2010.
[23]  H. Vees, S. Senthamizhchelvan, R. Miralbell, D. C. Weber, O. Ratib, and H. Zaidi, “Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 2, pp. 182–193, 2009.
[24]  M. Rickhey, O. Koelbl, C. Eilles, and L. Bogner, “A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors,” Strahlentherapie und Onkologie, vol. 184, no. 10, pp. 536–542, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133